EllenRx®Allergy/Immunology

Dupixent denied by insurance? What insurers ask for and how to appeal

dupilumab · Sources reviewed Nov 10, 2026 · Sources below

Used for
9 conditions (see above)
How it's given
Injection under the skin
Prior authorization usually required?
Varies by plan

What does my insurer usually ask for before approving Dupixent?

  • For eczema: tried prescription skin creams firstPlans want to see that prescription creams or ointments did not work well enough, or could not be used, before approving Dupixent.
  • For asthma: blood test showing high eosinophilsPlans ask for a blood test of eosinophils (a type of white blood cell), often at least 150 cells per microliter, unless you need daily steroid pills for asthma.
  • For asthma: still uncontrolled on daily inhalersPlans want proof your asthma stayed uncontrolled even while using a steroid inhaler plus another controller medicine.
  • Keep using your usual inhaler or nasal sprayDupixent is an add-on for asthma, COPD, and nasal polyps, so plans expect you to keep taking your regular daily medicine with it.
  • Prescribed by or with a specialistPlans usually want a specialist for your condition, such as a skin, allergy, lung, or stomach doctor, to prescribe or advise.
  • Not combined with similar biologic drugsPlans usually will not pay for Dupixent together with another biologic shot used for the same condition.

Typical first approval: First approvals often last 4 to 12 months, depending on the plan and condition.

Based on published policies from several large commercial insurers and the FDA label (see Sources). Medicare, Medicaid and other plans may use different rules. Your plan's rules may differ.

Why was Dupixent denied, and what can I do?

  1. Decode your denial letter: Ellen explains the reason in plain words.
  2. Check your denial type and your rights (Medicare or Medicaid if that's your coverage).
  3. Build your appeal, with the step-by-step appeal guide.
Decode my Dupixent denial

How can I lower the cost of Dupixent?

If you have Medicare or Medicaid, check each program's terms before you apply.

Safety information

From FDA-approved prescribing information for Dupixent (IL-4/IL-13 Inhibitor).

Do not use if

  • Clinically significant hypersensitivity to dupilumab

Key warnings

  • Do not abruptly discontinue corticosteroids when starting, taper gradually
  • Conjunctivitis and keratitis reported: ophthalmologic evaluation if eye symptoms develop
  • Eosinophilia may occur: monitor in patients with comorbid asthma

This is not a complete list. See the full Dupixent prescribing information or ask your pharmacist for complete safety information.

For clinicians: Dupixent prior authorization card (printable).

Sources: FDA prescribing information for Dupixent (DailyMed) and these insurers' published policies: Aetna (Policy Dupixent SGM 1690-A P2026b, page dated October 13, 2026), Anthem/Elevance (Publish date 09/10/2025; last review 08/15/2025), Cigna (Effective 06/15/2026), UnitedHealthcare (Effective 9/1/2026). Checked 2026-11-10. Sources reviewed Nov 10, 2026.

Not medical advice. This page is for educational and informational purposes only. It does not replace professional medical judgment. Always consult your prescribing physician or pharmacist before starting, stopping, or changing any medication. Ellen does not provide medical advice, diagnose conditions, or recommend treatments. Coverage rules vary by plan and change often; confirm with your plan's current policy.